Epkinly a novel drug approved by fda
Epkinly is a novel drug approved by fda (on last May 19) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma(DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. The IgG1 antibody Epcoritamab is manufactured in CHOcells. 👉 CHO cells play a fundamental role in […]